Literature DB >> 17901001

Determination of triethylenetetramine (TETA) and its metabolites in human plasma and urine by liquid chromatography-mass spectrometry (LC-MS).

Jun Lu1, Yi-Kai Chan, Sally D Poppitt, Garth J S Cooper.   

Abstract

A liquid chromatography-mass spectrometry (LC-MS) method has been developed to measure triethylenetetramine (TETA) and its metabolites in human samples. We identified two metabolites of TETA, N1-acetyltriethylenetetramine (MAT) and N1,N10-diacetyltriethylenetetramine (DAT), the latter being novel. We further developed this LC-MS method for the measurement of TETA and these metabolites in human plasma and urine in a single injection. Separation of analytes was achieved on a cyano column using 15% acetonitrile, 85% water (18 M Omega), and 0.1% heptafluorobutyric acid as the mobile phase. Simultaneous MS detection was performed at [M+H]+ values of 147, 189, 231 and 245, corresponding to TETA, MAT, DAT, and N1-acetylspermine as the internal standard, respectively. This method was successfully applied to measure TETA, MAT and DAT in plasma and urine of humans receiving oral drug treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17901001     DOI: 10.1016/j.jchromb.2007.09.001

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  6 in total

1.  Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments.

Authors:  J Lu; D Gong; S Y Choong; H Xu; Y-K Chan; X Chen; S Fitzpatrick; S Glyn-Jones; S Zhang; T Nakamura; K Ruggiero; V Obolonkin; S D Poppitt; A R J Phillips; G J S Cooper
Journal:  Diabetologia       Date:  2010-03-11       Impact factor: 10.122

2.  Complex N-acetylation of triethylenetetramine.

Authors:  Marc Cerrada-Gimenez; Janne Weisell; Mervi T Hyvönen; Myung Hee Park; Leena Alhonen; Jouko Vepsäläinen; Tuomo A Keinänen
Journal:  Drug Metab Dispos       Date:  2011-08-30       Impact factor: 3.922

Review 3.  Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.

Authors:  Garth J S Cooper
Journal:  Drugs       Date:  2011-07-09       Impact factor: 9.546

4.  3,12-Diaza-6,9-diazo-nia-2,13-dioxotetra-decane bis-(perchlorate).

Authors:  Tilo Söhnel; Kathrin A Wichmann; Thomas Doert; Garth J S Cooper
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-01-11

5.  Diabetic cardiomyopathy is associated with defective myocellular copper regulation and both defects are rectified by divalent copper chelation.

Authors:  Shaoping Zhang; Hong Liu; Greeshma V Amarsingh; Carlos C H Cheung; Sebastian Hogl; Umayal Narayanan; Lin Zhang; Selina McHarg; Jingshu Xu; Deming Gong; John Kennedy; Bernard Barry; Yee Soon Choong; Anthony R J Phillips; Garth J S Cooper
Journal:  Cardiovasc Diabetol       Date:  2014-06-14       Impact factor: 9.951

6.  Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairment.

Authors:  Jun Lu; Beau Pontré; Stephen Pickup; Soon Y Choong; Mingming Li; Hong Xu; Gregory D Gamble; Anthony R J Phillips; Brett R Cowan; Alistair A Young; Garth J S Cooper
Journal:  Cardiovasc Diabetol       Date:  2013-01-31       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.